A mutation in QRDR in the ParC subunit of topoisomerase IV was responsiblefor fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae

Citation
H. Choi et al., A mutation in QRDR in the ParC subunit of topoisomerase IV was responsiblefor fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae, YONSEI MED, 39(6), 1998, pp. 541-545
Citations number
27
Categorie Soggetti
General & Internal Medicine
Journal title
YONSEI MEDICAL JOURNAL
ISSN journal
05135796 → ACNP
Volume
39
Issue
6
Year of publication
1998
Pages
541 - 545
Database
ISI
SICI code
0513-5796(199812)39:6<541:AMIQIT>2.0.ZU;2-5
Abstract
Forty-one strains of Streptococcus pneumoniae were isolated at Seoul Nation al University Children's Hospital from 1991 to 1997. Isolates were divided into six groups based on MICs of three quinolones, ciprofloxacin, ofloxacin and norfloxacin. Sequencing showed that the isolates which were intermedia tely resistant to three quinolones or resistant to at least one kind of qui nolone had one missense mutation, Lys137 --> Asn (AAG --> AAT) substitution in the ParC subunit of topoisomerase IV without additional mutation in QRD R of the GyrA subunit of DNA gyrase. In conclusion, the ParC subunit of DNA topoisomerase IV is the primary target site for fluoroquinolone in S. pneu moniae and Lys137 --> Asn substitution renders the quinolone resistance in S. pneumoniae..